xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05963451</url>
    </required_header>
    <id_info>
      <org_study_id>2022-4293</org_study_id>
      <nct_id>NCT05963451</nct_id>
    </id_info>
    <brief_title>Brain, Psychological and Epigenetic Determinants for Optimizing the Treatment of Chronic Low Back Pain</brief_title>
    <official_title>Assessing the Predictability of Brain, Psychological and Epigenetic Determinants for Optimizing the Treatment of Chronic Low Back Pain</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Université de Sherbrooke</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Université de Sherbrooke</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The goal of this observational study is to better understand the role of the brain in chronic&#xD;
        low back pain patients.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Chronic pain affects millions of people worldwide, and the main cardinal sign of any&#xD;
        arthritis condition is pain. Several arthritis conditions can cause chronic low back pain&#xD;
        (CLBP).The mechanisms that contribute to CLBP are not yet fully understood, but considering&#xD;
        the role of the brain in the context of chronic pain, it is only logical to investigate&#xD;
        structural and functional brain properties in CLBP, in order to improve diagnosis and&#xD;
        treatment of this condition.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Anticipated">September 7, 2023</start_date>
    <completion_date type="Anticipated">July 16, 2027</completion_date>
    <primary_completion_date type="Anticipated">July 16, 2027</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Other</observational_model>
      <time_perspective>Retrospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>Change of Grey matter volume</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>Grey matter volume (milliliters cube) will be measured by acquiring a T1weighted (T1w) image using Magnetic Resonance Imaging.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Change of Blood-oxygen level dependent (BOLD) response</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>Blood-oxygen level dependent (BOLD) response will be measured by using functional Magnetic Resonance Imaging (fMRI).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Change of Microstructural and connectivity properties of white matter tracts</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>Microstructural and connectivity properties will be measured by using diffusion Magnetic Resonance Imaging (dMRI).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Change of Brain's arteries system</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>Brain vasculature will be measured by using Time-of-Flight Magnetic Resonance Angiography (ToF MRA).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Change of Brain's venous system</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>Brain vasculature will be measured by using Susceptibility Weighted Imaging (SWI).</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Change of Pain Severity score</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>The investigators will use the Brief Pain Inventory-short form (BPI-SF). Measured on a numerical rating scale (0 = &quot;no pain&quot; to 10 = &quot;worst pain imaginable&quot;). Higher score means worse outcome.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change of Pain Interference score</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>The investigators will use the Brief Pain Inventory-short form (BPI-SF). Measured on a numerical rating scale (0 = &quot;no interference&quot; to 10 = &quot;complete interference&quot;). Higher score means worse outcome.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change of Pain Catastrophizing score</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>The investigators will use the Pain Catastrophizing-short form (PCS-SF). Measured on a 5-point Likert-scale (0 = &quot;not at all&quot; to 4 = &quot;all the time&quot;). Higher score means worse outcome.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change of Neuropathic pain components score</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>The investigators will use the Pain detect. Seven items are measured on a rated on a 6-point Likert Scale (0 = &quot;not at all&quot; to 5 = &quot;very strongly&quot;). Higher score means worse outcome. 1 item based on pain behavior pattern score (-1, 0 or 1) and 1 item based on a radiation score (0 or 2).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change of Global function score</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>The investigators will use the Pain Outcomes Questionnaire (POQ). Measured on a numeric rating scale (0 = &quot;less symptoms&quot; to 10= &quot;more severe symptoms&quot;). Higher score means worse outcome.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change of Anxiety score</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>The investigators will use the State-Trait Anxiety Inventory (STAI-S/T). Measured on a 4-point Likert-scale (0 = &quot;not at all&quot; to 3 = &quot;all the time&quot;).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change of Depression score</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>The investigators will use the Beck Depression Inventory (BDI). Measured on a 4-point Likert-scale (0 = &quot;less symptoms&quot; to 3 = &quot;more severe symptoms&quot;). Higher score means worse outcome.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change of Fear of movement score</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>The investigators will use the Tampa Scale of Kinesiophobia - short form (TSK-SF).Measured on a 4-point Likert-scale (0 = &quot;Strongly Disagree&quot; to 3 = &quot;Strongly Agree&quot;). Higher score means worse outcome.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change of Functional disability score</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>The investigators will use the Oswestry Disability Index (ODI). Measured on a 6-point Likert Scale (0 = &quot;less symptoms&quot; to 5 = &quot;more severe symptoms&quot;). Higher score means worse outcome.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change of Insomnia severity score</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>The investigators will use the Insomnia severity Index (ISI). Measured on a 5-point Likert scale (0 = &quot;not at all&quot; to 4 = &quot;extremely&quot;). Higher score means worse outcome.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of traumatic events</measure>
      <time_frame>Change from Baseline (4 weeks before their treatment) and after their treatment (at 4 months post treatment)</time_frame>
      <description>The investigators will use the Life Events Checklist (LEC). We will count the number of traumatic events.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Patient Expectations score</measure>
      <time_frame>This will be acquired 1 week before their treatment</time_frame>
      <description>The investigators will use the EXPECT Questionnaire. Measured on numerical rating scale (0 = &quot;no change&quot; to 10 = &quot;complete relief&quot;). Higher score means better outcome.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change of Global Impression score</measure>
      <time_frame>Change from Baseline (at 2 months post treatment) and after 2 months (at 4 months post treatment)</time_frame>
      <description>The investigators will use the Patients' Global Impression of Change (PGIC) scale. Measured on numerical rating scale (0 = &quot;no change&quot; to 10 = &quot;complete relief&quot;). Higher score means better outcome.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change Central sensitization component score</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>The investigators will use the Central Sensitization Inventory - short form (CSI-SF). Measured on a 5-point Likert-scale (0 = &quot;never&quot; to 4 = &quot;always&quot;). Higher score means worse outcome.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Patient Gender score</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>The investigators will use a Short Gender Questionnaire (SGQ). Measured on a 5-point Likert-scale (1 = &quot;not at all&quot; to 5 = &quot;extremely&quot;).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change Polygenic methylation score</measure>
      <time_frame>Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)</time_frame>
      <description>The investigators will acquire a saliva sample using a DNA kit to perform epigenetic analysis.</description>
    </secondary_outcome>
    <number_of_groups>1</number_of_groups>
    <enrollment type="Anticipated">80</enrollment>
    <condition>Chronic Low-back Pain</condition>
    <arm_group>
      <arm_group_label>Chronic Low Back Pain (CLBP) group</arm_group_label>
      <description>Participants who will took part in our study are people living with CLBP who will undergo facet thermal ablation treatment</description>
    </arm_group>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>No intervention</intervention_name>
      <description>No intervention will be given in our study since, the investigators are recruiting people who will receive already a facet thermal ablation.</description>
      <arm_group_label>Chronic Low Back Pain (CLBP) group</arm_group_label>
    </intervention>
    <biospec_retention>Samples With DNA</biospec_retention>
    <biospec_descr>
      <textblock>
        Saliva samples to perform epigenetic analysis.&#xD;
      </textblock>
    </biospec_descr>
    <eligibility>
      <study_pop>
        <textblock>
          -People with CLBP who will have a thermoablation of medial lumbar branches by&#xD;
          radiofrequency&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Low back pain (≥ 6 months) with or without pain radiating to the legs or radiating to&#xD;
               the neck&#xD;
  &#xD;
            -  Positive medial branch blocks, suggesting that the pain originates from the lumbar&#xD;
               facet joints&#xD;
  &#xD;
            -  Average pain intensity of ≥ 3/10 in the 24-hour period before the initial visit&#xD;
  &#xD;
            -  Pain primarily localized in the lower back&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Inadequate pain relief or relief of less than three months following selective&#xD;
               thermoablation of medial lumbar branches by radiofrequency&#xD;
  &#xD;
            -  Neurological, cardiovascular, or pulmonary disorders&#xD;
  &#xD;
            -  Comorbid pain syndrome&#xD;
  &#xD;
            -  History of surgical intervention in the back&#xD;
  &#xD;
            -  A corticosteroid infiltration within the past year&#xD;
  &#xD;
            -  Pregnancy (current or planned during the course of the study)&#xD;
  &#xD;
            -  Contra-indication to Magnetic Resonance Imaging (MRI)&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>75 Years</maximum_age>
    </eligibility>
    <overall_contact>
      <last_name>Pascal Tétreault, PhD</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>12858</phone_ext>
      <email>pascal.tetreault@usherbrooke.ca</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Marylie Martel, PhD</last_name>
      <email>marylie.martel@usherbrooke.ca</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS)</name>
        <address>
          <city>Sherbrooke</city>
          <state>Quebec</state>
          <zip>J1H 5N4</zip>
          <country>Canada</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Pascal Tétreault, PhD</last_name>
        <phone>+1 819 821-8000</phone>
        <phone_ext>74502</phone_ext>
        <email>pascal.tetreault@usherbrooke.ca</email>
      </contact>
      <contact_backup>
        <last_name>Marylie Martel, PhD</last_name>
        <phone>+1 819 346-1110</phone>
        <phone_ext>12858</phone_ext>
        <email>marylie.martel@usherbrooke.ca</email>
      </contact_backup>
    </location>
    <location_countries>
      <country>Canada</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>July 10, 2023</study_first_submitted>
    <study_first_submitted_qc>July 18, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">July 27, 2023</study_first_posted>
    <last_update_submitted>September 11, 2023</last_update_submitted>
    <last_update_submitted_qc>September 11, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 13, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Back Pain</mesh_term>
      <mesh_term>Low Back Pain</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05963451
  org study id: 2022-4293
  nct id: NCT05963451
  lead sponsor: 
  has dmc: Yes
  is fda regulated drug: No
  is fda regulated device: No
  The goal of this observational study is to better understand the role of the brain in chronic
        low back pain patients.
  Chronic pain affects millions of people worldwide, and the main cardinal sign of any
        arthritis condition is pain. Several arthritis conditions can cause chronic low back pain
        (CLBP).The mechanisms that contribute to CLBP are not yet fully understood, but considering
        the role of the brain in the context of chronic pain, it is only logical to investigate
        structural and functional brain properties in CLBP, in order to improve diagnosis and
        treatment of this condition.
  observational model: Other
  time perspective: Retrospective
  measure: Change of Grey matter volume
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: Grey matter volume (milliliters cube) will be measured by acquiring a T1weighted (T1w) image using Magnetic Resonance Imaging.
  measure: Change of Blood-oxygen level dependent (BOLD) response
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: Blood-oxygen level dependent (BOLD) response will be measured by using functional Magnetic Resonance Imaging (fMRI).
  measure: Change of Microstructural and connectivity properties of white matter tracts
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: Microstructural and connectivity properties will be measured by using diffusion Magnetic Resonance Imaging (dMRI).
  measure: Change of Brain's arteries system
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: Brain vasculature will be measured by using Time-of-Flight Magnetic Resonance Angiography (ToF MRA).
  measure: Change of Brain's venous system
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: Brain vasculature will be measured by using Susceptibility Weighted Imaging (SWI).
  measure: Change of Pain Severity score
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: The investigators will use the Brief Pain Inventory-short form (BPI-SF). Measured on a numerical rating scale (0 = "no pain" to 10 = "worst pain imaginable"). Higher score means worse outcome.
  measure: Change of Pain Interference score
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: The investigators will use the Brief Pain Inventory-short form (BPI-SF). Measured on a numerical rating scale (0 = "no interference" to 10 = "complete interference"). Higher score means worse outcome.
  measure: Change of Pain Catastrophizing score
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: The investigators will use the Pain Catastrophizing-short form (PCS-SF). Measured on a 5-point Likert-scale (0 = "not at all" to 4 = "all the time"). Higher score means worse outcome.
  measure: Change of Neuropathic pain components score
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: The investigators will use the Pain detect. Seven items are measured on a rated on a 6-point Likert Scale (0 = "not at all" to 5 = "very strongly"). Higher score means worse outcome. 1 item based on pain behavior pattern score (-1, 0 or 1) and 1 item based on a radiation score (0 or 2).
  measure: Change of Global function score
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: The investigators will use the Pain Outcomes Questionnaire (POQ). Measured on a numeric rating scale (0 = "less symptoms" to 10= "more severe symptoms"). Higher score means worse outcome.
  measure: Change of Anxiety score
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: The investigators will use the State-Trait Anxiety Inventory (STAI-S/T). Measured on a 4-point Likert-scale (0 = "not at all" to 3 = "all the time").
  measure: Change of Depression score
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: The investigators will use the Beck Depression Inventory (BDI). Measured on a 4-point Likert-scale (0 = "less symptoms" to 3 = "more severe symptoms"). Higher score means worse outcome.
  measure: Change of Fear of movement score
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: The investigators will use the Tampa Scale of Kinesiophobia - short form (TSK-SF).Measured on a 4-point Likert-scale (0 = "Strongly Disagree" to 3 = "Strongly Agree"). Higher score means worse outcome.
  measure: Change of Functional disability score
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: The investigators will use the Oswestry Disability Index (ODI). Measured on a 6-point Likert Scale (0 = "less symptoms" to 5 = "more severe symptoms"). Higher score means worse outcome.
  measure: Change of Insomnia severity score
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: The investigators will use the Insomnia severity Index (ISI). Measured on a 5-point Likert scale (0 = "not at all" to 4 = "extremely"). Higher score means worse outcome.
  measure: Number of traumatic events
  time frame: Change from Baseline (4 weeks before their treatment) and after their treatment (at 4 months post treatment)
  description: The investigators will use the Life Events Checklist (LEC). We will count the number of traumatic events.
  measure: Patient Expectations score
  time frame: This will be acquired 1 week before their treatment
  description: The investigators will use the EXPECT Questionnaire. Measured on numerical rating scale (0 = "no change" to 10 = "complete relief"). Higher score means better outcome.
  measure: Change of Global Impression score
  time frame: Change from Baseline (at 2 months post treatment) and after 2 months (at 4 months post treatment)
  description: The investigators will use the Patients' Global Impression of Change (PGIC) scale. Measured on numerical rating scale (0 = "no change" to 10 = "complete relief"). Higher score means better outcome.
  measure: Change Central sensitization component score
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: The investigators will use the Central Sensitization Inventory - short form (CSI-SF). Measured on a 5-point Likert-scale (0 = "never" to 4 = "always"). Higher score means worse outcome.
  measure: Patient Gender score
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: The investigators will use a Short Gender Questionnaire (SGQ). Measured on a 5-point Likert-scale (1 = "not at all" to 5 = "extremely").
  measure: Change Polygenic methylation score
  time frame: Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment)
  description: The investigators will acquire a saliva sample using a DNA kit to perform epigenetic analysis.
  arm group label: Chronic Low Back Pain (CLBP) group
  description: Participants who will took part in our study are people living with CLBP who will undergo facet thermal ablation treatment
  intervention type: Other
  intervention name: No intervention
  description: No intervention will be given in our study since, the investigators are recruiting people who will receive already a facet thermal ablation.
  arm group label: Chronic Low Back Pain (CLBP) group
  Saliva samples to perform epigenetic analysis.
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 75 Years
  last name: Pascal Tétreault, PhD
  phone: 819-346-1110
  phone ext: 12858
  email: pascal.tetreault@usherbrooke.ca
  last name: Marylie Martel, PhD
  email: marylie.martel@usherbrooke.ca
  facility: 
  status: Recruiting
  contact: 
  contact backup: 
  country: Canada
  responsible party type: Sponsor
  mesh term: Back Pain
  mesh term: Low Back Pain
  sharing ipd: No